To NASDAQ OMX Copenhagen A/S Announcement no. 09-14 /
Copenhagen, May 8, 2014 Topotargetannounces that the Board of Directors has reviewed and approved the company’s interim report for the period January 1– March 31, 2014. Highlights from the financial results for the period January 1 - March 31, 2014-- Topotargetrecognized revenues of DKK 98.2 millionduring the period ( DKK 0.4 millionin the same period in 2013) -- The research and development costs were DKK 4.3 millionduring the period ( DKK 6.1 millionin the same period in 2013) -- The administrative expenses were DKK 3.3 millionduring the period ( DKK 3.8 millionin the same period in 2013) -- Non-recurring items were DKK 5.8 millionduring the period ( DKK 0.0 millionin the same period in 2013) -- The net financials were a net loss of DKK 1.8 millionduring the period (net loss of DKK 0.4 millionin the same period in 2013) -- The net profit from continued operations before tax for the period was DKK 82.8 million(net loss of DKK 10.2 millionfor the same period in 2013) -- Total comprehensive income for the period was a net profit of DKK 75.3 million(net loss of DKK 10.2 millionfor the same period in 2013) -- The Group’s net cash and cash equivalents as of March 31, 2014totaled DKK 109.7 million( DKK 31.5 millionat year-end 2013) At a teleconference, which will be held today at 1.00 pm CET, CEO Anders Vadsholtwill present the interim report for the period January 1– March 31, 2014and answer questions. The teleconference will be conducted in English. A presentation will be available on Topotarget’s website, www.topotarget.com, before the start of the teleconference. To participate in the teleconference, please dial: -- Denmark: 32 72 80 18 -- International: +44 (0) 1452 555131 Conference ID: 18951138 You will be able to stream the teleconference via the following link: http://www.media-server.com/m/p/r84qxzpt After the call, a playback will be available via the same link. Topotarget A/SFor further information, please contact: Anders Vadsholt, CEO – direct: +45 39178345 Background information About Topotarget Topotarget(NASDAQ OMX: TOPO) is a Scandinavian-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to the clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotargetfocuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to www.topotarget.com. Topotarget Safe Harbor Statement This announcement may contain forward-looking statements, including statements about Topotarget A/S’ expectations to the progression of Topotarget A/S’ clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/Sdisclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law. Copyright © 2014 OMX AB (publ).